问题 › 我们不知道谁是最佳客户 › 健康科技与数字健康
最佳并非指注册人数最多，而是指那些能在可接受的毛利率水平下承担风险份额、参与率能支撑归因结果、且标识流失率低到可重复的群体。 数字健康公司面临一个具体困境——结果风险的签署速度快于公司判断自身能否承担的速度，12个月的测量窗口对上11个月的销售周期。在定价完成前，按风险分成收入的走向将持续无法归因，关于细分贡献的讨论也将停留在意见层面。
最佳并非指注册人数最多，而是指那些能在可接受的毛利率水平下承担风险份额、参与率能支撑归因结果、且标识流失率低到可重复的群体。 数字健康公司面临一个具体困境——结果风险的签署速度快于公司判断自身能否承担的速度，12个月的测量窗口对上11个月的销售周期。在定价完成前，按风险分成收入的走向将持续无法归因，关于细分贡献的讨论也将停留在意见层面。
数字健康运营商能按注册成员总数和ARR列出合同，但很少能单独识别出在按风险分成收入后贡献为正、PMPM服务成本可控、且以标识流失率衡量的留存稳定的群体，因为这些数据分散在理赔、参与和财务系统中。
由此产生的排序与规划中使用的排序始终不同。成员数量最多的合同在应用参与率和归因结果后往往排名下降；保留利润的群体多来自早期试点，却从未转化为可重复的获客细分。
这一区分决定下一份结果风险合同如何签署、PMPM定价如何设定、哪些人群获得进一步产品投入、哪些标识获得续约，因此误判最佳细分意味着销售周期和12个月测量窗口都围绕错误的经济学优化。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 领导层复盘按注册成员数或ARR对活跃合同排序，而非按风险分成收入后的净边际和参与率排序。
✓ PMPM成本和毛利率仅在账簿总体层面报告，没有与标识流失率挂钩的群体或细分拆分。
✓ 新销售使用的目标画像来自现有最大合同，而非已证明稳定归因结果和低流失的群体。
通常会让情况更糟的做法。 从注册成员最多的合同出发撰写理想客户画像，这会选中那些能最大限度争取风险分成让步的客户，而非能盈利承担结果风险的群体。
It is for you if you run or finance a digital health company and best customer means largest by revenue in internal conversation. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Monetize the largest three-condition outcomes dataset to subsidize outcomes risk and generate 13% growth without increasing at-risk share.
The leak it closes. Reduces dependence on 38% at-risk PMPM revenue by adding non-at-risk, high-margin revenue stream
The assumption it rests on. State privacy laws do not mandate patient-level consent for de-identified data before 2029 — the engine put the probability at 0.7.
| Investment required | $1.8–2.4M over 18 months |
| Expected return | 2.3–3.8× on $2.1M midpoint investment within 36 months |
| Revenue, year 1 | $0.8–1.2M ARR (3–4 deals) |
| Revenue, year 2 | $2.4–3.6M ARR (9–12 deals) |
| Revenue, year 3 | $4.2–6.8M ARR (15–20 deals) |
| Exit criteria | Kill move if fewer than 2 deals ≥$150k ACV close by Month 12 OR if any state privacy statute requiring patient-level consent for de-identified data is enacted before Month 18; reallocate remaining budget to Clinical Coaching Capacity Marketplace node |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Customer Value Architecture, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
在细分层面合并贡献、获客成本和留存。三者中任意单一维度都会产生一个自信但错误的排序。
这通常是好消息——它给出明确的定向指令。相关问题是该群体是否足够大到支撑增长计划，这个问题有答案。
先重新定价；部分会转为盈利，其余则自行离开。直接放弃更快，但会损失哪些可重新定价的信息。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית